CAR T-cell therapy positively benefitted patients with patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Breyanzi (lisocabtagene maraleucel), ...

After reading a book about how Imbruvica was revolutionized for SLL and CLL, I now have a greater appreciation for the drugs I receive. As a patient diagnosed with small lymphocytic lymphoma (SLL), my ...

Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL) are types of slow-growing cancers that affect a type of white blood cell called a lymphocyte. Lymphocytes are cells that help ...

Zanubrutinib shows safety and efficacy in CLL/SLL patients, regardless of prior ibrutinib treatment, with lower treatment-limiting and cardiac adverse events compared to ibrutinib. The study included ...

About 50% of patients with CLL/SLL have high-risk molecular features limiting effectiveness of certain treatments; a blood test can identify these features and help guide which therapy is most likely ...

Statin use in CLL/SLL patients treated with ibrutinib reduced cancer-related death risk by 61% and improved survival outcomes. The study found no significant increase in severe side effects with ...

Pirtobrutinib, a highly selective, noncovalent Bruton’s tyrosine kinase inhibitor (BTKi), shows substantial improvements in progression-free survival over the chemotherapy regimen of bendamustine plus ...

The treatment patterns and adverse reactions of bevacizumab in the Chinese population in the real world.

Patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who were taking cholesterol-lowering statin medications at the start of their cancer treatment had a 61% lower risk ...